ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0562

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Abstract Number: 0563

Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Abstract Number: 0564

Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Abstract Number: 0565

Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Abstract Number: 0566

Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
Abstract Number: 0567

Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Abstract Number: 0568

Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
Abstract Number: 0569

ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Abstract Number: 0570

Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Abstract Number: 0571

Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Abstract Number: 0572

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Abstract Number: 0573

Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Abstract Number: 0574

Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Abstract Number: 0575

Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Abstract Number: 0576

Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].